A device for processing samples is disclosed. Interior surfaces of the device, which come in contact with fluids, define wetted surfaces. A portion of the wetted surfaces are coated with an alkylsilyl coating having the Formula I: ##STR00001##
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are each independently selected from (C.sub.1-C.sub.6)alkoxy, —NH(C.sub.1-C.sub.6)alkyl, —N((C.sub.1-C.sub.6)alkyl).sub.2, OH, OR.sup.A, and halo. R.sup.A represents a point of attachment to the interior surfaces of the fluidic system. At least one of R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 is OR.sup.A. X is (C.sub.1-C.sub.20)alkyl, —O[(CH.sub.2).sub.2O].sub.1-20—, —(C.sub.1-C.sub.10)[NH(CO)NH(C.sub.1-C.sub.10)].sub.1-20—, or —(C.sub.1-C.sub.10)[alkylphenyl(C.sub.1-C.sub.10)alkyl].sub.1-20—.

The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.

The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.

The present invention provides a novel IGFR-like receptor and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of diabetes.

Provided herein are compositions and methods for assessing arrestin-dependent signaling. The provided compositions include fusion proteins comprising arrestin polypeptides that bind strongly to G protein-coupled receptors (GPCRs). In some instances, the fusion proteins may also bind to non-GPCR proteins, such as single transmembrane receptors and non-receptor proteins. Also provided are nucleic acids, vectors, constructs, and host cells that encode or express such fusion proteins. Also provided are methods of using such fusion proteins to assess arrestin trafficking, localization, and other functions including, for example, arrestin-mediated GPCR signaling as well as non-GPCR protein activity or signaling.

A reference standard set for BNP measurement, including a plurality of reference standards including BNP-32 and proBNP, wherein the ratio BNP-32/proBNP (mole ratio) differs between the reference standards, and when a reference standard having a high mole ratio and a reference standard having a low mole ratio are compared, the BNP concentration, which is the sum total of the BNP-32 concentration and the proBNP concentration, is lower in the reference standard having a high mole ratio than in the reference standard having a low mole ratio. The present invention makes it possible to provide: a reference standard set for BNP measurement, whereby, when the BNP concentration value of a specimen measured by a certain BNP measurement method and the BNP concentration value of the specimen measured by another BNP measurement method are corrected using the reference standard set for BNP measurement, the corrected measurement values can be made to more closely coincide in comparison with a case in which the measurement values are corrected using a conventional reference standard; and a method for correcting, using the reference standard set for BNP measurement, the measured BNP concentration value of a specimen.

A reference standard set for BNP measurement, including a plurality of reference standards including BNP-32 and proBNP, wherein the ratio BNP-32/proBNP (mole ratio) differs between the reference standards, and when a reference standard having a high mole ratio and a reference standard having a low mole ratio are compared, the BNP concentration, which is the sum total of the BNP-32 concentration and the proBNP concentration, is lower in the reference standard having a high mole ratio than in the reference standard having a low mole ratio. The present invention makes it possible to provide: a reference standard set for BNP measurement, whereby, when the BNP concentration value of a specimen measured by a certain BNP measurement method and the BNP concentration value of the specimen measured by another BNP measurement method are corrected using the reference standard set for BNP measurement, the corrected measurement values can be made to more closely coincide in comparison with a case in which the measurement values are corrected using a conventional reference standard; and a method for correcting, using the reference standard set for BNP measurement, the measured BNP concentration value of a specimen.

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

A glycemic management related analyte detecting assay device (10) and method are provided for detecting and quantifying analyte concentrations in a fluid sample. The assay device includes an absorbent body containing an assay forming a detection zone for receiving a fluid test sample. The absorbent body is provided in a chamber of the device. The assay can detect one or more of a glycemic analyte selected from the group consisting of fasting plasma blood glucose, oral glucose, % glycated hemoglobin, and fasting insulin concentrations. In one embodiment, a container includes an absorbent body having a plurality of superimposed membranes (30, 32, 34, 36) where each membrane contains a reactant and a color indicator for detecting the presence of a selected analyte above a predetermined concentration in the fluid sample. The absorbent body and/or the assay include a color indicator that is able to provide a visual indication of the presence of one or more glycemic analytes present in the test sample.